Lille (France), Cambridge (Massachusetts, United States), May 3 rd , 2016 - GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announced the publication of the fees of the statutory auditors in accordance with article 222-8 of the General Regulation of the French Autorité des marchés financiers .


Fees paid to statutory auditors Ernst & Young & AutresGrant ThorntonAine & Deldicque Associés
excl. VAT
% Amount
excl. VAT
% Amount
excl. VAT
(in € thousands) 201520142015201420152014201520142015201420152014
Auditing, certification of financial statements,              
examination of parent company and consolidated financial statements              
  - Issuer 807837%56%251984%100% 0 0%
  - Fully consolidated subsidiaries 000%0%000%0% 0 0%
Other tasks and services              
directly related to the audit              
  - Issuer 1396263%44%5016%0% 5 100%
  - Fully consolidated subsidiaries 000%0%000%0% 0 0%
Sous-total   220 140 100% 100% 30 19 100% 100%   5   100%
Other services provided by the networks to fully consolidated subsidiaries                          
Legal, tax, social 000%0%000%0% 0 0%
Others (specifiy if > 10% of audition fees) 000%0%000%0% 0 0%
Sub-total   0 0 0% 0% 0 0 0% 0%   0   0%
Total   220 140 100% 100% 30 19 100% 100%   5   100%

This table is available on the Company's website at, in the section "Investors/Documentation Center".

*English version for information purposes only.

The table has been translated in English for information purposes only; in the event of any differences between the text in French and the text in English, the French version shall supersede.


GENFIT is a biopharmaceutical company focused on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT's R&D efforts are focused on bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) and more generally the gastro-intestinal arena. GENFIT's approach combines novel treatments and biomarkers. Its lead proprietary compound, Elafibranor, is currently in a Phase 3 study. With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT - ISIN: FR0004163111).

Forward Looking Statement / Disclaimer:

This release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, including related to biomarkers, results of clinical data from the RESOLVE-IT trial, review and approvals by regulatory authorities, such as the FDA or the EMA, regarding in particular, Elafibranor in NASH and PBC, as well as other indications, and biomarkers, the success of any inlicensing strategies, the Company's continued ability to raise capital to fund its development, as well as those discussed or identified in the Company's public filings with the AMF, including those listed under  Section 4.2 "Risk Factors" ("Facteurs de Risque") of the Company's Annual Financial Report for the year ended December 31, 2015, which is available on GENFIT's website ( Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements.

This release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

2016.05.03 Release GENFIT Statuatory Auditors Fees

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: GENFIT via GlobeNewswire